Wird geladen...
A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) of potential use in patients with breast cancer. Unfortunately, in clinical studies, gefitinib is often ineffective indicating that resistance to EGFR inhibitors may be a common occurrence in cancer of the breast...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2012
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3858180/ https://ncbi.nlm.nih.gov/pubmed/22687878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.yexcr.2012.06.001 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|